Meeting
2017 ASCO Annual Meeting
Patient-reported outcomes and quality of life in ALTA: The randomized phase 2 study of brigatinib (BRG) in advanced ALK+ non–small cell lung cancer (NSCLC).
Authors
Corey J. Langer
University of Pennsylvania Abramson Cancer Center, Philadelphia, PA
Corey J. Langer , Hui Huang , Joice Huang , David Kerstein , William Reichmann , Rebecca M Speck , William R Lenderking
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Lung Cancer—Non-Small Cell Metastatic
Track
Lung Cancer
Sub Track
Metastatic Non–Small Cell Lung Cancer
Clinical Trial Registration Number
NCT02094573
Citation
J Clin Oncol 35, 2017 (suppl; abstr 9066)
DOI
10.1200/JCO.2017.35.15_suppl.9066
Abstract #
9066
Poster Bd #
392
Abstract Disclosures
Similar Posters
Poster
2012 ASCO Annual Meeting
Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer (NSCLC).
First Author: Dong-Wan Kim
Poster
2019 ASCO Annual Meeting
Phase 2 study of brigatinib in patients (pts) with anaplastic lymphoma kinase (ALK)−positive, advanced non–small cell lung cancer (NSCLC) that progressed on alectinib or ceritinib.
First Author: Edward S. Kim
Poster
2013 ASCO Annual Meeting
Impact of crizotinib on patient-reported symptoms and quality of life (QOL) compared with single-agent chemotherapy in a phase III study of advanced ALK+ non-small cell lung cancer (NSCLC).
First Author: Vera Hirsh
Poster
2023 ASCO Quality Care Symposium
Comparative cost-effectiveness analysis of oral agents for advanced EGFR mutated and ALK-positive non-small cell lung cancer.
First Author: Dali Edwards